A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

Alexandre Chan; Michael C. Cameron; Benjamin Garden; Christine B. Boers-Doets; Katja Schindler; Joel B. Epstein; Jennifer Choi; Laura Beamer; Eric Roeland; Elvio G. Russi; René Jean Bensadoun; Yi Ling Teo; Raymond J. Chan; Vivianne Shih; Jane Bryce; Judith Raber-Durlacher; Peter Arne Gerber; César O. Freytes; Bernardo Rapoport; Nicole LeBoeuf; Vincent Sibaud; Mario E. Lacouture

doi:10.1007/s00520-014-2564-x

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

Alexandre Chan, Michael C. Cameron, Benjamin Garden, Christine B. Boers-Doets, Katja Schindler, Joel B. Epstein, Jennifer Choi, Laura Beamer, Eric Roeland, Elvio G. Russi, René Jean Bensadoun, Yi Ling Teo, Raymond J. Chan, Vivianne Shih, Jane Bryce, Judith Raber-Durlacher, Peter Arne Gerber, César O. Freytes, Bernardo Rapoport, Nicole LeBoeufVincent Sibaud, Mario E. Lacouture

Mays Cancer Center

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments. Results: Thirteen articles identifying six PRO instruments met the inclusion criteria.

Original language	English (US)
Pages (from-to)	2231-2244
Number of pages	14
Journal	Supportive Care in Cancer
Volume	23
Issue number	8
DOIs	https://doi.org/10.1007/s00520-014-2564-x
State	Published - Aug 29 2015

Keywords

Dermatologic adverse events
Health-related quality of life
Patient-reported outcomes
Targeted cancer therapy

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s00520-014-2564-x

Cite this

Chan, A., Cameron, M. C., Garden, B., Boers-Doets, C. B., Schindler, K., Epstein, J. B., Choi, J., Beamer, L., Roeland, E., Russi, E. G., Bensadoun, R. J., Teo, Y. L., Chan, R. J., Shih, V., Bryce, J., Raber-Durlacher, J., Gerber, P. A., Freytes, C. O., Rapoport, B., ... Lacouture, M. E. (2015). A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Supportive Care in Cancer, 23(8), 2231-2244. https://doi.org/10.1007/s00520-014-2564-x

Chan, A, Cameron, MC, Garden, B, Boers-Doets, CB, Schindler, K, Epstein, JB, Choi, J, Beamer, L, Roeland, E, Russi, EG, Bensadoun, RJ, Teo, YL, Chan, RJ, Shih, V, Bryce, J, Raber-Durlacher, J, Gerber, PA, Freytes, CO, Rapoport, B, LeBoeuf, N, Sibaud, V & Lacouture, ME 2015, 'A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies', Supportive Care in Cancer, vol. 23, no. 8, pp. 2231-2244. https://doi.org/10.1007/s00520-014-2564-x

@article{8e3e39767ffb4eaaba7c727e1d27fa34,

title = "A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies",

abstract = "Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments. Results: Thirteen articles identifying six PRO instruments met the inclusion criteria.",

keywords = "Dermatologic adverse events, Health-related quality of life, Patient-reported outcomes, Targeted cancer therapy",

author = "Alexandre Chan and Cameron, {Michael C.} and Benjamin Garden and Boers-Doets, {Christine B.} and Katja Schindler and Epstein, {Joel B.} and Jennifer Choi and Laura Beamer and Eric Roeland and Russi, {Elvio G.} and Bensadoun, {Ren{\'e} Jean} and Teo, {Yi Ling} and Chan, {Raymond J.} and Vivianne Shih and Jane Bryce and Judith Raber-Durlacher and Gerber, {Peter Arne} and Freytes, {C{\'e}sar O.} and Bernardo Rapoport and Nicole LeBoeuf and Vincent Sibaud and Lacouture, {Mario E.}",

note = "Funding Information: Dr. Gerber has a consultant role with Galderma International. He is also receiving research funding from Hoffman La Roche. Funding Information: Dr. Lacouture has a consultant role with AstraZeneca, Roche, Bayer, Janssen, Exelixis, Advancell, BMS, Amgen and Genentech. He is also receiving research funding from Berg, Roche and BMS. Publisher Copyright: {\textcopyright} 2015, Springer-Verlag Berlin Heidelberg.",

year = "2015",

month = aug,

day = "29",

doi = "10.1007/s00520-014-2564-x",

language = "English (US)",

volume = "23",

pages = "2231--2244",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "8",

}

TY - JOUR

T1 - A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

AU - Chan, Alexandre

AU - Cameron, Michael C.

AU - Garden, Benjamin

AU - Boers-Doets, Christine B.

AU - Schindler, Katja

AU - Epstein, Joel B.

AU - Choi, Jennifer

AU - Beamer, Laura

AU - Roeland, Eric

AU - Russi, Elvio G.

AU - Bensadoun, René Jean

AU - Teo, Yi Ling

AU - Chan, Raymond J.

AU - Shih, Vivianne

AU - Bryce, Jane

AU - Raber-Durlacher, Judith

AU - Gerber, Peter Arne

AU - Freytes, César O.

AU - Rapoport, Bernardo

AU - LeBoeuf, Nicole

AU - Sibaud, Vincent

AU - Lacouture, Mario E.

N1 - Funding Information: Dr. Gerber has a consultant role with Galderma International. He is also receiving research funding from Hoffman La Roche. Funding Information: Dr. Lacouture has a consultant role with AstraZeneca, Roche, Bayer, Janssen, Exelixis, Advancell, BMS, Amgen and Genentech. He is also receiving research funding from Berg, Roche and BMS. Publisher Copyright: © 2015, Springer-Verlag Berlin Heidelberg.

PY - 2015/8/29

Y1 - 2015/8/29

N2 - Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments. Results: Thirteen articles identifying six PRO instruments met the inclusion criteria.

AB - Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments. Results: Thirteen articles identifying six PRO instruments met the inclusion criteria.

KW - Dermatologic adverse events

KW - Health-related quality of life

KW - Patient-reported outcomes

KW - Targeted cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=84933183142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933183142&partnerID=8YFLogxK

U2 - 10.1007/s00520-014-2564-x

DO - 10.1007/s00520-014-2564-x

M3 - Article

C2 - 25564221

AN - SCOPUS:84933183142

SN - 0941-4355

VL - 23

SP - 2231

EP - 2244

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 8

ER -

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this